Australia's most trusted
source of pharma news
Thursday, 07 November 2024
Posted 4 November 2024 AM
The TGA has given an insight into potential new rivalries for 2025, dropping a 15-strong list of drugs accepted for review in September.
Five new drugs on the regulator's desk, including Novartis' radiopharmaceutical agent Lutathera for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in adults.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.